Business
Minerva Neurosciences, Inc.: Our Business The summary of risks below provides an overview of the principal risks that we are exposed to in the normal course of our business activities.
Net income decreased 20492.7% to ($293.4M), while Operating cash flow increased 30.9% to ($13.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($293.4M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Minerva Neurosciences, Inc.'s own filings, the day they're filed.
- Consulting Period · departureeff. 2026-04-15
- Geoffrey Race · President · departureeff. 2026-03-31
- Inderjit Kaul · director · appointment
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Minerva Neurosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.